Scinai Immunotherapeutics Ltd. has executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l. and submitted a revised application for €12 million in non-dilutive funding through the European Funds for the Modern Economy SMART Path program. The company seeks this substantial grant to support an integrated €15 million research and development program for PC111, representing 80% co-financing for the project.
The amendment extends the option condition deadline to August 31, 2026, and the exercise period to September 30, 2026, aligning with the anticipated three- to four-month grant review timeline. This strategic timing allows Scinai to advance PC111 toward early clinical development and human proof of concept while maintaining flexibility in its acquisition plans. The company's newsroom provides ongoing updates about these developments at https://ibn.fm/SCNI.
PC111 represents a significant therapeutic opportunity as a fully human monoclonal antibody targeting soluble Fas Ligand for the treatment of pemphigus vulgaris and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis. These severe autoimmune conditions currently have limited treatment options, making PC111's development particularly important for patients suffering from these debilitating diseases. The full press release detailing these developments is available at https://ibn.fm/NmtDv.
The funding application through the SMART Path program represents a strategic move to secure non-dilutive, non-repayable capital, which would allow Scinai to advance its immunology pipeline without diluting shareholder value. This approach demonstrates prudent financial management while pursuing potentially transformative medical treatments. The company operates a contract development and manufacturing organization alongside its focused immunology R&D pipeline, creating a diversified business model that supports both service revenue and proprietary drug development.
For business and technology leaders in the biopharmaceutical sector, Scinai's dual-track approach offers insights into how companies can balance immediate revenue generation through CDMO services with long-term value creation through proprietary drug development. The extended timeline for the PinCell acquisition provides additional flexibility while the grant application progresses, potentially creating a more favorable position for completing the transaction if funding is secured. This development highlights the importance of strategic timing in biotech acquisitions and funding applications, particularly when pursuing European grant opportunities that require careful alignment with review processes and development milestones.
